| CZECH, Julia, Sabrina CORDUA, Barbora WEINBERGEROVÁ, Julian BAUMEISTER, Assja CREPCIA, Lijuan HAN, Tiago MAIÉ, Ivan G. COSTA, Bernd DENECKE, Angela MAURER, Claudia SCHUBERT, Kristina FELDBERG, Deniz GEZER, Tim H. BRÜMMENDORF, Gerhard MÜLLER-NEWEN, Jiří MAYER, Zdeněk RÁČIL, Blanka KUBEŠOVÁ, Trine KNUDSEN, Anders L. SØRENSEN, Morten HOLMSTRÖM, Lasse KJÆR, Vibe SKOV, Thomas S. LARSEN, Hans C. HASSELBALCH, Nicolas CHATAIN and Steffen KOSCHMIEDER. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation. Leukemia. London: Nature Publishung, 2019, vol. 33, No 4, p. 995-1010. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-018-0295-6. |
Other formats:
BibTeX
LaTeX
RIS
@article{1476877,
author = {Czech, Julia and Cordua, Sabrina and Weinbergerová, Barbora and Baumeister, Julian and Crepcia, Assja and Han, Lijuan and Maié, Tiago and Costa, Ivan G. and Denecke, Bernd and Maurer, Angela and Schubert, Claudia and Feldberg, Kristina and Gezer, Deniz and Brümmendorf, Tim H. and MüllerandNewen, Gerhard and Mayer, Jiří and Ráčil, Zdeněk and Kubešová, Blanka and Knudsen, Trine and Sørensen, Anders L. and Holmström, Morten and Kjær, Lasse and Skov, Vibe and Larsen, Thomas S. and Hasselbalch, Hans C. and Chatain, Nicolas and Koschmieder, Steffen},
article_location = {London},
article_number = {4},
doi = {http://dx.doi.org/10.1038/s41375-018-0295-6},
keywords = {Ph negative myeloproliferative disease; JAK2V617F; CALR; interferon alpha; molecular response},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation},
url = {https://www.ncbi.nlm.nih.gov/pubmed/30470838},
volume = {33},
year = {2019}
}
TY - JOUR
ID - 1476877
AU - Czech, Julia - Cordua, Sabrina - Weinbergerová, Barbora - Baumeister, Julian - Crepcia, Assja - Han, Lijuan - Maié, Tiago - Costa, Ivan G. - Denecke, Bernd - Maurer, Angela - Schubert, Claudia - Feldberg, Kristina - Gezer, Deniz - Brümmendorf, Tim H. - Müller-Newen, Gerhard - Mayer, Jiří - Ráčil, Zdeněk - Kubešová, Blanka - Knudsen, Trine - Sørensen, Anders L. - Holmström, Morten - Kjær, Lasse - Skov, Vibe - Larsen, Thomas S. - Hasselbalch, Hans C. - Chatain, Nicolas - Koschmieder, Steffen
PY - 2019
TI - JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation
JF - Leukemia
VL - 33
IS - 4
SP - 995-1010
EP - 995-1010
PB - Nature Publishung
SN - 08876924
KW - Ph negative myeloproliferative disease
KW - JAK2V617F
KW - CALR
KW - interferon alpha
KW - molecular response
UR - https://www.ncbi.nlm.nih.gov/pubmed/30470838
L2 - https://www.ncbi.nlm.nih.gov/pubmed/30470838
N2 - Pegylated interferon-alpha (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30-40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F-vs. calreticulin (CALR)-mutated cells and investigated the mechanisms of differential response. Retrospective analysis of MPN patients treated with peg-IFNa demonstrated that patients harboring the JAK2V617F mutation were more likely to achieve PMR than those with mutated CALR (p = 0.004), while there was no significant difference in hematological response. In vitro experiments confirmed an upregulation of IFN-stimulated genes in JAK2V617F-positive 32D cells as well as patient samples (peripheral blood mononuclear cells and CD34+ hematopoietic stem cells) compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR- as in JAK2V617F-mutant 32D cells. Additionally, Janus-activated kinase-1 (JAK1) and signal transducers and activators of transcription 1 (STAT1) showed constitutive phosphorylation in JAK2V617F-mutated but not CALR-mutated cells, indicating priming towards an IFNa response. Moreover, IFN-induced growth arrest was counteracted by selective JAK1 inhibition but enhanced by JAK2 inhibition. In conclusion, our data suggest that, clinically, higher doses of IFNa are needed in CALR-mutated vs. JAK2V617F-positive patients and we suggest a model of JAK2V617F-JAK1/ STAT1 crosstalk leading to a priming of JAK2V617F-positive cells to IFNa resulting in differential sensitivity.
ER -
CZECH, Julia, Sabrina CORDUA, Barbora WEINBERGEROVÁ, Julian BAUMEISTER, Assja CREPCIA, Lijuan HAN, Tiago MAIÉ, Ivan G. COSTA, Bernd DENECKE, Angela MAURER, Claudia SCHUBERT, Kristina FELDBERG, Deniz GEZER, Tim H. BRÜMMENDORF, Gerhard MÜLLER-NEWEN, Jiří MAYER, Zdeněk RÁČIL, Blanka KUBEŠOVÁ, Trine KNUDSEN, Anders L. SØRENSEN, Morten HOLMSTRÖM, Lasse KJÆR, Vibe SKOV, Thomas S. LARSEN, Hans C. HASSELBALCH, Nicolas CHATAIN and Steffen KOSCHMIEDER. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation. \textit{Leukemia}. London: Nature Publishung, 2019, vol.~33, No~4, p.~995-1010. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-018-0295-6.
|
